5 citations
,
August 2021 in “Journal of The European Academy of Dermatology and Venereology” In this phase 1B clinical trial, sublingual minoxidil was tested for its effects on male and female pattern hair loss in a randomized, double-blind, placebo-controlled setting, but the abstract does not provide specific results or conclusions.
January 2026 in “Frontiers in Pharmacology” This review reports that topical minoxidil remains the primary treatment for androgenetic alopecia, while oral and sublingual forms offer alternative options, each with varying efficacy and side effects.
September 2024 in “Actas Dermo-Sifiliográficas” Sublingual minoxidil is a safe and effective treatment for hair loss, especially in women.
March 2026 in “Mini-Reviews in Medicinal Chemistry” This review reports that pharmacogenomic variations in the SULT1A1 enzyme significantly influence the response to minoxidil treatment for alopecia, suggesting personalized therapeutic strategies could improve efficacy while emerging pharmaceutical technologies aim to optimize oral minoxidil's absorption and minimize side effects.
5 citations
,
April 2013 in “Nasza Dermatologia Online” This study reports no new clinical results on oral zinc therapy for acrodermatitis enteropathica but provides demographic data and symptom prevalence among thirty affected children.